Objective: To evaluate the efficacy and safety of single dose intravenous iron carboxymaltose vs multidose iron sucrose in postpartum cases of severe iron deficiency anemia.
INTRODUCTION
Iron deficiency is the most common nutritional deficiency worldwide; it affects 1.6 billion people (nearly a quarter of the world's population). 1 Lack of iron supplementation during pregnancy and postpartum hemorrhage (PPH) are important causes of postpartum anemia (PPA). This is because pregnancy requires about 1000 mg of additional iron, which cannot be met by the typical diet. 2, 3 Randomized clinical trials have shown that lack of prenatal iron supplementation is associated with low ferritin stores throughout the postpartum period. Similarly, women with IDA especially during the third trimester of pregnancy are more likely to suffer from PPA (postpartum anemia). It is also because IDA increases the risk of postpartum hemorrhage in these women. PPH is also an important cause of postpartum anemia. 4 Over the past years, various routine methods, like oral iron, intramuscular iron and blood transfusions were used to treat anemia during postpartum period, but these methods have some defiencies. [5] [6] [7] Orally, given iron has side effects, like intolerance, nausea, vomiting, epigastric pain, diarrhea, constipation, unpredictable absorption rate and poor compliance. 8 Iron sorbitol given intramuscularly cause considerable pain, skin staining, bleeding, tissues necrosis, arthralgia, myalgia, sterile abscess atrophy and sarcoma formation. So, to treat these conditions, we require a new mode of iron therapy with better efficacy, less side effects and better compliance. Intravenous iron carboxymaltose therapy seems to be a safe, convenient and more effective method for treating anemia during postpartum period than intravenous iron sucrose therapy.
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OBJECTIVES
The present study 'a study to compare the efficacy and safety of single dose intravenous iron carboxymaltose 
MATERIALS AND METHODS
Study was carried out in the Department of Obstetrics and Gynecology, SN Medical College, Agra, during a 2 year duration from October 2012 to 2014.
Sample Size
The study comprised of 100 cases which are to be randomly distributed into two groups consisting of 50 cases each.
Group A: Fifty cases in this group receive intravenous iron carboxymaltose therapy.
Group B: Fifty cases in this group receive intravenous iron sucrose therapy.
Inclusion Criteria
• All primi and multi patient • All normal delivered and caesarean delivered patient • Within 6 week of delivery.
Exclusion Criteria
• Patients with hemoglobin levels more than 7 gm% Group B: Intravenous injections (iron sucrose complex) They are available as ampules of 2.5 ml containing 50 mg of elemental iron.
Iron sucrose complex was given as 200 mg elemental iron (2 ampules of 5 ml) in 100 ml of 0.9% normal saline infusion over 30 minutes alternate days up to 5 days. The mean hemoglobin level before starting therapy in group A was 6.14 gm/dl. The mean hemoglobin level before starting therapy in group B was 6.06 gm/dl Grade 1 (adverse reaction): headache, nausea, abdominal pain, constipation, diarrhea, rashes, injection site reaction. Grade 2 (adverse reaction): hypersensitivity reaction including anaphylacoid reaction, paresthesia, dyspnea, dysguesia, vomiting, pruritus, urticaria, myalgia, arthalgia, backpain, fever, fatigue 
OBSERVATIONS
DISCUSSION
The mean age in group A was 25.30 years and mean age in group B was 25.56 years (Table 1) . In group A, 20% cases were primiparous and 80% cases were multiparous ( Table 2) . Majority of the cases belonged to lower middle status (class IV) according to modified BJ Prasad classification in both the groups (Table 3) .
So, in the present study, we found that the mean hemoglobin level before starting therapy in group A was 6.14 gm/dl and in group B was 6.06 gm/dl (Table 4) , there JSAFOG was an increase of 2.52 gm/dl in hemoglobin level after 2 weeks of therapy and mean hemoglobin level was 8.66 gm/dl in group A and in group B there was an increase of 1.95 gm/dl in hemoglobin level and the hemoglobin level was 8.01 gm/dl at 2 weeks after therapy (Table 5) . This difference further increased at 4 weeks after therapy. The hemoglobin level was 10.01 gm/dl in group A (rise of 3.95 gm/dl) at 4 weeks of therapy and in group B hemoglobin level was 9.38 gm/dl (rise of 3.32 gm/dl) ( Table 6 ). Mean hematological parameters increased significantly after 4 weeks in FCM group vs iron sucrose group (Table 7) . Improvement of mean hematological parameter is more in group A than group B after 4 weeks of iron therapy. In group A, 84% cases achieved the target hemoglobin at 8 weeks after therapy and 100% cases achieved target hemoglobin at 12 weeks after therapy. In group B, 80% cases achieved the target hemoglobin at 8 weeks after therapy and 98% cases achieved target hemoglobin at 12 weeks after therapy (Table 8) . In group A, 92% cases were completely relieved of there symptoms at 4 weeks after therapy and in group B only 84% cases were completely relieved of there symptoms. In group A only 12% cases had grade I adverse effects and in group B 20% cases had grade I adverse effects. None of the case in both the groups had grade II adverse effects (Table 9 ). So, we can say that the intravenous iron carboxymaltose therapy is more effective and safe therapy to treat iron deficiency anemia during postpartum period. In Breymann et al study in postpartum period showed that the mean Hb rise was 3.37 g/dl in FCM group and 3.29 g/dl in ferrous sulphate group after 12 weeks of iron therapy. 9 In Seid et al study in postpartum women, FCM group women achieved target hemoglobin (>12 gm%) in higher number of patient as compared to iron sucrose after 6 weeks of iron therapy. 10 In the study done by Von Wyck et al Hb rise greater than or equal to 2 gm/dl in FCM group than oral iron therapy after 6 weeks of iron therapy.
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CONCLUSION
In the present study, the cases selected in both the groups were comparable in terms of age, parity, and socioeconomic status. The mean hemoglobin level achieved in intravenous iron carboxymaltose group was significantly higher and the rate of increase in hemoglobin level was also significantly higher in intravenous iron carboxymaltose group. The number of cases achieving target hemoglobin was significantly higher in intravenous iron carboxymaltose group. The incidence of adverse effects was also significantly lower in intravenous iron carboxymaltose group. Thus, we can conclude that intravenous iron carboxymaltose therapy is safe, convenient, more effective and faster acting than intravenous iron sucrose therapy for the treatment of severe iron deficiency anemia during postpartum period.
